A recent article published in Paediatric Drugs reported that new, targeted biologic therapies for asthma have emerged as effective add-on options, complementing our expanding understanding of asthma phenotypes/endotypes and the underlying immunopathology of the disease spectrum. These include omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab. The authors stated that omalizumab represents the first available therapeutic option for allergic asthma in patients as young as six years of age. Its efficacy and safety have been established by several randomized controlled trials specifically conducted in pediatric patients, leading to its final registration, more than 10 years ago. In addition, three new interleukin (IL)-5 targeted agents, mepolizumab, reslizumab and benralizumab, have been approved for the treatment of severe eosinophilic asthma starting from six years of age, and varying by country. Recently, dupilumab, a targeted agent against the interleukin (IL)-4 receptor α-chain, was approved for patients ≥12 years of age in the United States, after pivotal trials were completed. This article stated that late-stage clinical testing of these targeted agents has mostly involved patients aged 12 years and above and the application of those data to younger children can be inappropriate and may carry risk. Therefore, it was suggested that the efficacy and safety of these newer biologics in children should be supported by adequate research within this targeted age group.